Last $12.56 USD
Change Today -0.10 / -0.79%
Volume 38.1K
VCYT On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Open
$12.66
Previous Close
$12.66
Day High
$12.66
Day Low
$12.35
52 Week High
03/19/14 - $19.00
52 Week Low
11/7/13 - $10.88
Market Cap
269.9M
Average Volume 10 Days
120.0K
EPS TTM
$-7.64
Shares Outstanding
21.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignancy Classifiers for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

115 Employees
Last Reported Date: 03/20/14
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $380.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $201.0K
Chief Commercial Officer
Total Annual Compensation: $316.3K
Compensation as of Fiscal Year 2013.

veracyte inc (VCYT) Key Developments

Veracyte, Inc. Reports Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Reiterates Revenue Guidance for the Year 2014

Veracyte, Inc. reported unaudited financial results for the second quarter and six months ended June 30, 2014. For the second quarter, the company’s revenue was $8.7 million, an increase of 71%, compared to $5.1 million for the second quarter of 2013. Net loss and comprehensive loss was $6.7 million, or $0.31 per common share, compared with a net loss of $6.5 million, or $7.53 per common share, for the comparable period in 2013. Loss from operations was $6.561 million against $5.417 million a year ago. For the six months, the company's revenue was $16.2 million, compared to $9.5 million for the same period in 2013, also an increase of 71%. Loss from operations was $13.136 million against $11.310 million a year ago. Net loss and comprehensive loss was $13.329 million, or $0.63 per basic and diluted share, compared with a net loss of $13.385 million, or $16.47 per basic and diluted share, for the comparable period in 2013. The company reiterates its 2014 revenue guidance of $38 million to $43 million.

Veracyte, Inc. to Report Q2, 2014 Results on Aug 13, 2014

Veracyte, Inc. announced that they will report Q2, 2014 results After-Market on Aug 13, 2014

Veracyte, Inc., Q2 2014 Earnings Call, Aug 13, 2014

Veracyte, Inc., Q2 2014 Earnings Call, Aug 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $12.56 USD -0.10

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
TrovaGene Inc $5.84 USD -0.17
View Industry Companies
 

Industry Analysis

VCYT

Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.3x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERACYTE INC, please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.